Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles & Nanoparticle Therapeutics Europe 2022

Maurizio Muraca's Biography



Maurizio Muraca, Professor, Università degli Studi di Padova

Maurizio Muraca, MD (Padova), PhD (Leuven) is Professor of Internal Medicine and Chief of Regenerative Medicine at the Department of Women’s and Children’s Health at the University of Padova. From 2004 to 2014 he was?Head of Clinical Chemistry and Microbiology and responsible for the Regenerative Medicine research area at the Bambino Gesù Hospital in Rome. From 1997 to 2000 he coordinated the first clinical study in Italy on the treatment of liver failure with a bioartificial liver as part of an international FDA-approved trial. In 2000 he performed the first clinical hepatocyte transplantation in Europe after a series of studies in large animal models. During the last decade, he investigated the use of extracellular vesicles as therapeutic tool.

Maurizio Muraca Image

Mesenchymal Stromal Cell-derived Extracellular Vesicles as Therapeutic Tool in Neonatology: The Case of Bronchopulmonary Dysplasia

Monday, 24 October 2022 at 11:45

Add to Calendar ▼2022-10-24 11:45:002022-10-24 12:45:00Europe/LondonMesenchymal Stromal Cell-derived Extracellular Vesicles as Therapeutic Tool in Neonatology: The Case of Bronchopulmonary DysplasiaExtracellular Vesicles and Nanoparticle Therapeutics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Extreme premature newborns are a fragile population because of immaturity of various organs, requiring variable stays in the ICU. Bronchopulmonary Dysplasia is the most common respiratory disease in babies, resulting in high mortality and high incidence of long-lasting complications and for which no definite cure exists. Treatment with mesenchymal stromal cells (MSCs) and more recently with MSC-derived extracellular vesicles has provided proof-of-principle in animal models and is now entering the clinical phase.   In addition to providing preclinical evidence and to complying with regulatory requirements, the therapeutic approach to this peculiar patient population requires a delicate balance between efficacy and potential risks.


Add to Calendar ▼2022-10-24 00:00:002022-10-25 00:00:00Europe/LondonExtracellular Vesicles and Nanoparticle Therapeutics Europe 2022Extracellular Vesicles and Nanoparticle Therapeutics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com